Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ARTEMIS Clear all
Recruiting Phase 3 Interventional

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281
View directory record Official record
Conditions
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Interventions
Ziltivekimab, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
188
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 156 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 5, 2026, 5:26 PM EDT
Active, not recruiting Not applicable Interventional

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

NCT02276443
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Lymph Node Biopsy, Ultrasonography
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 5, 2026, 5:26 PM EDT
Terminated Phase 3 Interventional Results available

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

NCT00879229
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Ambrisentan, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
51
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 5, 2026, 5:26 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

NCT01390220
View directory record Official record
Conditions
Epilepsy
Interventions
USL261, Placebo
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 5, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Impact of Synbiotic Supplementation on Infants and Toddlers

NCT06746285
View directory record Official record
Conditions
Gastrointestinal Tolerance of Probiotics in Infants
Interventions
Synbiotic Supplement, Lactose (inactive placebo)
Dietary Supplement
Lead sponsor
Persephone Biosciences
Industry
Eligibility
2 Months to 24 Months
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 5, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability of Aronia Berry Polyphenols

NCT05488886
View directory record Official record
Conditions
Gut Health, Metabolism, Polyphenols
Interventions
Whole Aronia Berry Powder Applesauce, Aronia Berry Extract Applesauce, Phospholipid-Polyphenol Applesauce, Low-Polyphenol Control Applesauce
Dietary Supplement · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Sep 5, 2026, 5:26 PM EDT
Terminated Phase 3 Interventional Results available

(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

NCT00768300
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Ambrisentan, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
40 Years to 80 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 5, 2026, 5:26 PM EDT
Not yet recruiting Not applicable Interventional

Advanced Robotic Techniques and Rapid Onsite Evaluation for Minimally Invasive Diagnosis and Next-Generation Sequencing.

NCT07685977
View directory record Official record
Conditions
Peripheral Pulmonary Lesions (PPLs)
Interventions
Rapid onsite evaluation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • Burlington, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 5, 2026, 5:26 PM EDT
Terminated Phase 2 Interventional Results available

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)

NCT02357147
View directory record Official record
Conditions
Mesothelioma, Malignant
Interventions
Placebo, Amatuximab, Pemetrexed, Cisplatin
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
La Jolla, California • Newark, Delaware • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 5, 2026, 5:26 PM EDT
Terminated Not applicable Interventional Results available

Comparative Analysis of Transperineal Versus Transrectal Approaches for MRI-Targeted Biopsy of the Prostate for the Detection and Characterization of Prostate Cancer

NCT03366792
View directory record Official record
Conditions
Prostate Cancer
Interventions
Artemis™ software system
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Sep 5, 2026, 5:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19

NCT06147063
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection
Interventions
AZD9838, Licensed SARS-CoV-2 mRNA vaccine, AZD6563
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
5
States / cities
Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 5, 2026, 5:26 PM EDT
Recruiting Not applicable Interventional

Project neuroARTEMIS

NCT06814275
View directory record Official record
Conditions
Stimulant Use, Human Immunodeficiency Virus (HIV), Depression
Interventions
ARTEMIS, Contingency management for Antiretroviral (ARV) adherence
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 59 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 5:26 PM EDT
Terminated No phase listed Observational

PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase

NCT04178746
View directory record Official record
Conditions
Intracerebral Hemorrhage, Brain Hemorrhage, Intraventricular Hemorrhage
Interventions
Artemis Neuro Evacuation Device
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Summit, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 5, 2026, 5:26 PM EDT
Completed Early Phase 1 Interventional

Focal Laser Ablation of Prostate Cancer

NCT04305925
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal Laser Ablation
Device
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 5, 2026, 5:26 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

NCT06577935
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
AGA2118, Placebo
Drug · Other
Lead sponsor
Angitia Biopharmaceuticals
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Gainesville, Georgia • Albuquerque, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 5, 2026, 5:26 PM EDT
Terminated No phase listed Observational

ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing

NCT05380557
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Pancreatic Cancer, Resectable Pancreatic Cancer
Interventions
Germline genetic testing
Diagnostic Test
Lead sponsor
Invitae Corporation
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Sep 5, 2026, 5:26 PM EDT
Recruiting Phase 1Phase 2 Interventional

Autologous Gene Therapy for Artemis-Deficient SCID

NCT03538899
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
AProArt-CD34, CliniMACS® CD34 Reagent System cell sorter device, Busulfan
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Months and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2038
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 5, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

NCT04996797
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tulisokibart, Companion Diagnostic (CDx) Testing, Placebo
Drug · Device · Other
Lead sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
29
States / cities
Mobile, Alabama • Phoenix, Arizona • Sun City, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 5, 2026, 5:26 PM EDT
Terminated Phase 1 Interventional

Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

NCT03379493
View directory record Official record
Conditions
Lymphomas Non-Hodgkin's B-Cell
Interventions
ET190L1 ARTEMIS™ T cells
Biological
Lead sponsor
Eureka Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Sep 5, 2026, 5:26 PM EDT
Completed Not applicable Interventional Results available

INVEST-REGISTRY: Minimally Invasive Endoscopic Surgical Treatment With Apollo/Artemis in Patients With Brain Hemorrhage

NCT02661672
View directory record Official record
Conditions
Intracranial Hemorrhage
Interventions
Apollo Device, Artemis Device
Device
Lead sponsor
J. Mocco
Other
Eligibility
22 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Louisville, Kentucky • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 5, 2026, 5:26 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

NCT06856577
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
75
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 5, 2026, 5:26 PM EDT
Completed Not applicable Interventional Results available

MIND: Artemis in the Removal of Intracerebral Hemorrhage

NCT03342664
View directory record Official record
Conditions
Cerebral Hemorrhage, Brain Hemorrhage, Cerebral Parenchymal Hemorrhage, Intracerebral Hemorrhage
Interventions
Artemis + Medical Management, Best Medical Management Alone (MM)
Device · Other
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Mission Viejo, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 5, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Keratoconus Detection by Ultrasound

NCT01403129
View directory record Official record
Conditions
Keratoconus
Interventions
Artemis Ultrasound Exam, Optical Coherence Tomography (OCT) Exam
Procedure
Lead sponsor
Columbia University
Other
Eligibility
6 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 5, 2026, 5:26 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Artemis Sleep Countermeasures

NCT06531733
View directory record Official record
Conditions
Fatigue
Interventions
Sleep Promoting (pink noise), Wake Promoting (blue enriched light plus a nap)
Device
Lead sponsor
National Aeronautics and Space Administration (NASA)
Federal
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 5, 2026, 5:26 PM EDT